18 hasil untuk "Birgit Bremer"

Kinetics and Value of Hepatitis B Core-Related Antigen in Patients with Chronic Hepatitis B Virus Infection during Antiviral Treatment

Lisa Sandmann; Birgit Bremer; Valerie Ohlendorf dkk.

Viruses, Vol. 16 No. 2 · 2024 · Inggris · DOAJ Scopus

Background: The hepatitis B core-related antigen (HBcrAg) correlates with HBV DNA in patients with chronic HBV infection without antiviral treatment. Its utility in monitoring patients during and after the cessation of nucleos(t)ide analog (NA) treatment is unknown. Methods: The levels of HBcrAg…

Limited stability of Hepatitis B virus RNA in plasma and serum

Valerie Ohlendorf; Birgit Bremer; Lisa Sandmann dkk.

Scientific Reports, Vol. 14 No. 1 · 2024 · Inggris · DOAJ Scopus

Abstract Pregenomic hepatitis B virus RNA (HBV pgRNA) is a potential biomarker in the management of HBV infected patients. However, prior to the use in routine clinical practice potential confounders of test results need to be identified. This study investigates the stability of HBV pgRNA under…

Enhanced monitoring and detection of recent genotype 3 hepatitis E virus infection through urine antigen testing

Yannick Stahl; Iyad Kabar; Hauke Heinzow dkk.

Emerging Microbes and Infections, Vol. 12 No. 2 · 2023 · Inggris · DOAJ Scopus

Hepatitis E virus (HEV) is the leading cause of acute viral hepatitis. Numerous studies have investigated the dynamics of HEV infection markers, but the most suitable marker for diagnosing ongoing or recent HEV infection remains to be determined. Recent evidence suggests that serum antigen testing…

Performance of Two HCV RNA Assays during Protease Inhibitor-Based Triple Therapy in Patients with Advanced Liver Fibrosis and Cirrhosis

Benjamin Maasoumy; Bela Hunyady; Vincenza Calvaruso dkk.

PLoS ONE, Vol. 9 No. 11 · 2014 · Inggris · PLOS Scopus

Introduction: On-treatment HCV RNA measurements are crucial for the prediction of a sustained virological response (SVR) and to determine treatment futility during protease inhibitor-based triple therapies. In patients with advanced liver disease an accurate risk/benefit calculation based on…

Juga tersedia di: DOAJ

PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C

Antoaneta A. Markova; Ulrike Mihm; Verena Schlaphoff dkk.

PLoS ONE, Vol. 9 No. 4 · 2014 · Inggris · PLOS Scopus

Background: Ribavirin (RBV) remains part of several interferon-free treatment strategies even though its mechanisms of action are still not fully understood. One hypothesis is that RBV increases responsiveness to type I interferons. Pegylated Interferon alpha (PEG-IFNa) has recently been shown to…

Juga tersedia di: DOAJ

HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta

Lisa Sandmann; Cihan Yurdaydin; Katja Deterding dkk.

Hepatology Communications, Vol. 6 No. 3 · 2022 · Inggris · DOAJ Scopus

Standard treatment of hepatitis delta virus (HDV) infection remains pegylated‐interferon alfa (peg‐IFNα) in most centers, which is not only associated with rather low efficacy but several adverse events. Hepatitis B core‐related antigen (HBcrAg) is linked to intrahepatic covalently closed circular…

Increased HEV Seroprevalence in Patients with Autoimmune Hepatitis

Sven Pischke; Anett Gisa; Pothakamuri Venkata Suneetha dkk.

PLoS ONE, Vol. 9 No. 1 · 2014 · Inggris · PLOS Scopus

Background: Hepatitis E virus (HEV) infection takes a clinically silent, self-limited course in the far majority of cases. Chronic hepatitis E has been reported in some cohorts of immunocompromised individuals. The role of HEV infections in patients with autoimmune hepatitis (AIH) is unknown…

Juga tersedia di: DOAJ

Development and performance of prototype serologic and molecular tests for hepatitis delta infection

Kelly E. Coller; Emily K. Butler; Ka-Cheung Luk dkk.

Scientific Reports, Vol. 8 No. 1 · 2018 · Inggris · DOAJ Scopus

Abstract Worldwide, an estimated 5% of hepatitis B virus (HBV) infected people are coinfected with hepatitis delta virus (HDV). HDV infection leads to increased mortality over HBV mono-infection, yet HDV diagnostics are not widely available. Prototype molecular (RNA) and serologic (IgG) assays were…

Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study

Benjamin Maasoumy; Birgit Bremer; Patrick Lehmann dkk.

Therapeutic Advances in Gastroenterology, Vol. 10 · 2017 · Inggris · DOAJ Scopus

Background HBV DNA is the most important molecular marker in hepatitis B, used to determine treatment indication and monitoring. Most patients require lifelong hepatitis B virus (HBV) management, thus viral load (VL) monitoring may be performed at different laboratories, with different HBV assays…

Distinct clusters of bacterial and fungal microbiota in end-stage liver cirrhosis correlate with antibiotic treatment, intestinal barrier impairment, and systemic inflammation

Laura Buttler; David A. Velázquez-Ramírez; Anja Tiede dkk.

Gut Microbes, Vol. 17 No. 1 · 2025 · Inggris · DOAJ Scopus

Decompensated liver cirrhosis (dLC) is associated with intestinal dysbiosis, however, underlying reasons and clinical consequences remain largely unexplored. We investigated bacterial and fungal microbiota, their relation with gut barrier integrity, inflammation, and cirrhosis-specific…

Hepatitis delta virus co-infection in patients with hepatocellular carcinoma and people living with HIV in Nigeria

Ijeoma Ifeorah; Birgit Bremer; Yusuf Musa dkk.

BMC Infectious Diseases, Vol. 26 No. 1 · 2026 · Inggris · DOAJ Scopus

Abstract Introduction Despite Nigeria’s high burden of hepatitis B virus (HBV), the epidemiological landscape of hepatitis D virus (HDV) remains largely unexplored. Consequently, HDV remains under-recognized as a public health concern, slowing down efforts to improve surveillance and clinical care…

Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis

Anja Tiede; Lena Stockhoff; Zhaoli Liu dkk.

Clinical and Molecular Hepatology, Vol. 31 No. 1 · 2025 · Inggris · DOAJ Scopus

Background/Aims Systemic Inflammation (SI) is considered a key mechanism in disease progression and development of complications in decompensated liver cirrhosis. SI is mainly driven by portal hypertension and bacterial translocation. Transjugular intrahepatic portosystemic shunt (TIPS) insertion…

Treatment response to bulevirtide is linked to amelioration of portal hypertension in patients with chronic hepatitis D

Lisa Sandmann; Mathias Jachs; Tammo L. Tergast dkk.

JHEP Reports, Vol. 8 No. 1 · 2026 · Inggris · DOAJ Scopus

Background & Aims: Portal hypertension (PH) drives decompensation in patients with advanced chronic liver disease. Effects of antiviral treatment with bulevirtide (BLV) and achievement of suggested treatment endpoints on PH in patients with chronic hepatitis D (CHD) are unknown. Methods…

Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta

Anika Wranke; Benjamin Heidrich; Stefanie Ernst dkk.

PLoS ONE, Vol. 9 No. 7 · 2014 · Inggris · PLOS Scopus

Background: Hepatitis delta frequently leads to liver cirrhosis and hepatic decompensation. As treatment options are limited, there is a need for biomarkers to determine disease activity and to predict the risk of disease progression. We hypothesized that anti-HDV IgM could represent such a marker…

Juga tersedia di: DOAJ